On this page
Naglazyme
galsulfase
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Naglazyme
Proper name
galsulfase
Licence type
351(a)
BLA number
125117
Applicant
BioMarin Pharmaceutical Inc.
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 5MG/5ML (1MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | May 31, 2005 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | May 31, 2012 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |